Patents by Inventor Jean Y. J. Wang

Jean Y. J. Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Strategy for leukemia therapy
    Patent number: 7238525
    Abstract: The chimeric Bcr-Abl oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). In the cytoplasm, the protein transduces a growth signal that is responsible for overexpansion of cells. In the nucleus, the protein induces apoptosis. The invention is a method of treating cancer/killing Bcr-Abl expressing cells by inducing the translocation of Bcr-Abl to the nucleus to activate the apoptotic pathway in cancer cells.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: July 3, 2007
    Assignee: The Regents of the University of California
    Inventors: Jean Y. J. Wang, Paolo Vigneri
  • Strategy for leukemia therapy
    Publication number: 20030162740
    Abstract: The chimeric Bcr-Abl oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). In the cytoplasm, the protein transduces a growth signal that is responsible for overexpansion of cells. In the nucleus, the protein induces apoptosis. The invention is a method of treating cancer/killing Bcr-Abl expressing cells by inducing the translocation of Bcr-Abl to the nucleus to activate the apoptotic pathway in cancer cells.
    Type: Application
    Filed: December 27, 2002
    Publication date: August 28, 2003
    Inventors: Jean Y J Wang, Paolo Vigneri
  • Methods for the detection of BCR-ABL and abnormal ABL proteins in leukemia patients
    Patent number: 5369008
    Abstract: The present invention provides methods for detecting and quantitating BCR-ABL gene products and other abnormal ABL gene products of Ph.sup.1 -positive leukemic cells. The invention further provides methods for determining the relative number of leukemic cells compared with normal ABL cells to assess the tumor burden of a patient. In another aspect, the methods of the present invention can be used to determine a specific phase of leukemia, particularly chronic-phase CML.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: November 29, 1994
    Assignee: Board of Regents, The University of Texas System
    Inventors: Ralph B. Arlinghaus, Jean Y. J. Wang, Jie O. Guo